Clinical Trial Update: Alisertib in Chemotherapy-pretreated Urothelial Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of alisertib in chemotherapy-pretreated urothelial/bladder cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Transitional Cell Carcinoma

Drugs mentioned

• Alisertib (alisertib)

Snippet

Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Conditions: Bladder Cancer, Transitional Cell Carcinoma | Phase 2 | Status: COMPLETED